Characteristics of the study participants according to cGVHD status
. | No cGVHD, no. (%) . | P, none vs resolved . | Resolved cGVHD, no. (%) . | P, none vs active . | Active cGVHD, no. (%) . | P, resolved vs active . |
|---|---|---|---|---|---|---|
| Sex | .01 | .02 | .99 | |||
| Female | 140 (51.7) | 67 (39.6) | 57 (39.6) | |||
| Male | 131 (48.3) | 102 (60.4) | 87 (60.4) | |||
| Race/ethnicity | .63 | .68 | .45 | |||
| White | 206 (76.0) | 130 (76.9) | 113 (78.5) | |||
| Hispanic | 42 (15.5) | 18 (10.7) | 19 (13.2) | |||
| Other | 23 (8.5) | 21 (12.4) | 12 (8.3) | |||
| Institution | .25 | < .001 | < .001 | |||
| COH | 134 (49.4) | 74 (43.8) | 96 (66.7) | |||
| UMN | 137 (50.6) | 95 (56.2) | 48 (33.3) | |||
| Age at transplantation*† | < .001 | < .001 | .01 | |||
| Younger than 21 y | 93 (34.3) | 27 (16.0) | 14 (9.7) | |||
| 21-45 y | 152 (56.1) | 118 (69.8) | 96 (66.7) | |||
| Older than 45 y | 26 (9.6) | 24 (14.2) | 34 (23.6) | |||
| Age at interview†‡ | .06 | < .001 | .12 | |||
| 18-45 y | 192 (70.8) | 105 (62.1) | 77 (53.5) | |||
| Older than 45 y | 79 (29.2) | 64 (37.9) | 67 (46.5) | |||
| Time since transplantationठ| .12 | < .001 | < .001 | |||
| 2-5 y | 78 (28.8) | 52 (30.8) | 79 (54.9) | |||
| 6-10 y | 69 (25.5) | 58 (34.3) | 42 (29.2) | |||
| 11-28 y | 124 (45.8) | 59 (34.9) | 23 (16.0) | |||
| Year of transplantation | .002 | < .001 | .001 | |||
| 1975-1984 | 71 (26.2) | 16 (9.5) | 7 (4.9) | |||
| 1985-1994 | 122 (45.0) | 97 (57.4) | 64 (44.4) | |||
| 1995-1999 | 78 (28.8) | 56 (33.1) | 73 (50.7) | |||
| Diagnosis | .07 | .003 | .24 | |||
| Aplastic anemia | 31 (11.4) | 15 (8.9) | 10 (6.9) | |||
| Acute leukemia | 128 (47.2) | 70 (41.4) | 50 (34.7) | |||
| Lymphoma | 16 (5.9) | 11 (6.5) | 17 (11.8) | |||
| Immune disorder | 3 (1.1) | 1 (0.6) | 0 (0.0) | |||
| Chronic leukemia | 91 (33.6) | 72 (42.6) | 67 (46.5) | |||
| Other | 2 (0.7) | 0 (0.0) | 0 (0.0) | |||
| Stem cell source | .99 | .009 | .02 | |||
| Bone marrow | 257 (94.8) | 161 (95.3) | 128 (88.9) | |||
| Cord blood | 4 (1.5) | 1 (0.6) | 0 (0.0) | |||
| Peripheral blood stem cells | 10 (3.7) | 7 (4.1) | 16 (11.1) | |||
| Donor type | < .001 | < .001 | .14 | |||
| Related | 244 (90.0) | 132 (78.1) | 102 (70.8) | |||
| Unrelated | 27 (10.0) | 37 (21.9) | 42 (29.2) | |||
| Conditioning regimen | .02 | .06 | .71 | |||
| Chemotherapy | 35 (12.9) | 10 (5.9) | 10 (6.9) | |||
| Radiation and chemotherapy | 236 (87.1) | 159 (94.1) | 134 (93.1) | |||
| Education | .83 | .39 | .53 | |||
| Did not graduate from high school | 19 (7.0) | 11 (6.5) | 7 (4.9) | |||
| High school graduate | 252 (93.0) | 158 (93.5) | 137 (95.1) | |||
| Insurance | .77 | .19 | .14 | |||
| Insured at time of interview | 246 (90.8) | 152 (89.9) | 136 (94.4) | |||
| Uninsured at time of interview | 25 (9.2) | 17 (10.1) | 8 (5.6) | |||
| Annual household income | .66 | .68 | .45 | |||
| Less than $20 000 | 41 (15.1) | 23 (13.6) | 24 (16.7) | |||
| Greater than $20 000 | 230 (84.9) | 146 (86.4) | 120 (83.3) |
. | No cGVHD, no. (%) . | P, none vs resolved . | Resolved cGVHD, no. (%) . | P, none vs active . | Active cGVHD, no. (%) . | P, resolved vs active . |
|---|---|---|---|---|---|---|
| Sex | .01 | .02 | .99 | |||
| Female | 140 (51.7) | 67 (39.6) | 57 (39.6) | |||
| Male | 131 (48.3) | 102 (60.4) | 87 (60.4) | |||
| Race/ethnicity | .63 | .68 | .45 | |||
| White | 206 (76.0) | 130 (76.9) | 113 (78.5) | |||
| Hispanic | 42 (15.5) | 18 (10.7) | 19 (13.2) | |||
| Other | 23 (8.5) | 21 (12.4) | 12 (8.3) | |||
| Institution | .25 | < .001 | < .001 | |||
| COH | 134 (49.4) | 74 (43.8) | 96 (66.7) | |||
| UMN | 137 (50.6) | 95 (56.2) | 48 (33.3) | |||
| Age at transplantation*† | < .001 | < .001 | .01 | |||
| Younger than 21 y | 93 (34.3) | 27 (16.0) | 14 (9.7) | |||
| 21-45 y | 152 (56.1) | 118 (69.8) | 96 (66.7) | |||
| Older than 45 y | 26 (9.6) | 24 (14.2) | 34 (23.6) | |||
| Age at interview†‡ | .06 | < .001 | .12 | |||
| 18-45 y | 192 (70.8) | 105 (62.1) | 77 (53.5) | |||
| Older than 45 y | 79 (29.2) | 64 (37.9) | 67 (46.5) | |||
| Time since transplantationठ| .12 | < .001 | < .001 | |||
| 2-5 y | 78 (28.8) | 52 (30.8) | 79 (54.9) | |||
| 6-10 y | 69 (25.5) | 58 (34.3) | 42 (29.2) | |||
| 11-28 y | 124 (45.8) | 59 (34.9) | 23 (16.0) | |||
| Year of transplantation | .002 | < .001 | .001 | |||
| 1975-1984 | 71 (26.2) | 16 (9.5) | 7 (4.9) | |||
| 1985-1994 | 122 (45.0) | 97 (57.4) | 64 (44.4) | |||
| 1995-1999 | 78 (28.8) | 56 (33.1) | 73 (50.7) | |||
| Diagnosis | .07 | .003 | .24 | |||
| Aplastic anemia | 31 (11.4) | 15 (8.9) | 10 (6.9) | |||
| Acute leukemia | 128 (47.2) | 70 (41.4) | 50 (34.7) | |||
| Lymphoma | 16 (5.9) | 11 (6.5) | 17 (11.8) | |||
| Immune disorder | 3 (1.1) | 1 (0.6) | 0 (0.0) | |||
| Chronic leukemia | 91 (33.6) | 72 (42.6) | 67 (46.5) | |||
| Other | 2 (0.7) | 0 (0.0) | 0 (0.0) | |||
| Stem cell source | .99 | .009 | .02 | |||
| Bone marrow | 257 (94.8) | 161 (95.3) | 128 (88.9) | |||
| Cord blood | 4 (1.5) | 1 (0.6) | 0 (0.0) | |||
| Peripheral blood stem cells | 10 (3.7) | 7 (4.1) | 16 (11.1) | |||
| Donor type | < .001 | < .001 | .14 | |||
| Related | 244 (90.0) | 132 (78.1) | 102 (70.8) | |||
| Unrelated | 27 (10.0) | 37 (21.9) | 42 (29.2) | |||
| Conditioning regimen | .02 | .06 | .71 | |||
| Chemotherapy | 35 (12.9) | 10 (5.9) | 10 (6.9) | |||
| Radiation and chemotherapy | 236 (87.1) | 159 (94.1) | 134 (93.1) | |||
| Education | .83 | .39 | .53 | |||
| Did not graduate from high school | 19 (7.0) | 11 (6.5) | 7 (4.9) | |||
| High school graduate | 252 (93.0) | 158 (93.5) | 137 (95.1) | |||
| Insurance | .77 | .19 | .14 | |||
| Insured at time of interview | 246 (90.8) | 152 (89.9) | 136 (94.4) | |||
| Uninsured at time of interview | 25 (9.2) | 17 (10.1) | 8 (5.6) | |||
| Annual household income | .66 | .68 | .45 | |||
| Less than $20 000 | 41 (15.1) | 23 (13.6) | 24 (16.7) | |||
| Greater than $20 000 | 230 (84.9) | 146 (86.4) | 120 (83.3) |